Abstract
131I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1–3 doses of 3.33–4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patient had no symptoms before131I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 weekto 1 month after131I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from131I-MIBG therapy. Thus,131I-MIBG appears to be useful for the palliation of malignant pheochromocytoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma.N Engl J Med 305: 12–17, 1981.
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.J Nucl Med 26: 576–585, 1985.
Koizumi M, Endo K, Sakahara H, Nakashima T, Nakano Y, Nakao K, et al. Computed tomography and131I-MIBG scintigraphy in the diagnosis of pheochromocytoma.Acta Radiol Diag 27: 305–309, 1986.
Endo K, Shiomi K, Kasagi K, Konishi J, Torizuka K, Nakao K, et al. Imaging of medullary thyroid cancer with131I-MIBG.Lancet ii: 233, 1984.
Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine.J Nucl Med 28: 308–314, 1987.
Sisson JC, Shapiro B, Beierwaltes WH, Glowniac JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma.J Nucl Med 24: 197–206, 1984.
Aritake S. Radioisotope therapy of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine. Absorbed dose assessments using SPECT.KAKU IGAKU (Jpn J Nucl Med) 29: 667–678, 1992.
Okazawa H, Endo K, Saga T, Watanabe Y, Nakai T, Kasagi K, et al. Therapy of malignant pheochromocytoma using I-131 metaiodobenzylguanidine. Report of a case.Acta Radiol Jpn 50: 286–294, 1990
Hoefnagel CA. Radionuclide therapy revisited.Eur J Nucl Med 18: 408–431, 1991.
McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors.Semin Nucl Med 15: 132–153, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sakahara, H., Endo, K., Saga, T. et al. 131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma. Ann Nucl Med 8, 133–137 (1994). https://doi.org/10.1007/BF03165018
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03165018